US4029789A
Expired / Lapsed
US
⏱️ 0.0 years remaining
1-[2'-(α-Furoyl or α-thienoyl)eth-1'-yl]-2-(4"-cinnamyl piperazin-1"-yl methyl)benzimidazoles and method of using same
Assignee: Synthelabo SA
•
Filing: 1975-11-20
•
Granted: 1977-06-14
•
Expires: 1995-11-20
Abstract
Abstract Compounds of the formula <IMAGE> in which Ar is alpha -furyl or alpha -thienyl and pharmacologically acceptable salts thereof are provided as novel therapeutic agents which have inter alia utility in treating asthma, respiratory deficiency, visceral spasms, gastroduodenal ulcers or hyperchlorhydria.
Inventors
- 👤 Claude P. Fauran
- 👤 Nicole Dorme
- 👤 Guy M. Raynaud
- 👤 Jeannine Eberle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 07:09
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/14; A; A61; A61P; A61P1/00; A61P1/04; A61P11/00; A61P11/08; A61P11/16; C07D409/00; C07D409/14
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
21 words
A compound having the formula ##STR11## in which Ar is α-furyl or α-thienyl, and the pharmacologically acceptable acid addition salts thereof.
Claim 2
Dependent Claim
21 words
A compound having the formula ##STR11## in which Ar is α-furyl or α-thienyl, and the pharmacologically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
12 words
A compound as claimed in claim 1 in which Ar is α-furyl.
Claim 4
Dependent Claim
10 words
The dimaleate salt of the compound claimed in claim 2.
Claim 5
Dependent Claim
12 words
A compound as claimed in claim 1 in which Ar is α-thienyl.
Claim 6
Dependent Claim
10 words
The dimaleate salt of the compound claimed in claim 4.
Claim 7
Dependent Claim
38 words
A composition for treating a condition of asthma, respiratory deficiency, visceral spasms, gastroduodenal ulcers or hyperchlorhydria, comprising an effective amount of a compound as claimed in claim 1 for treating the condition, together with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
31 words
A method for treating asthma which comprises administering to a host suffering from asthma a therapeutically effective amount of a compound as claimed in claim 1, with a pharmaceutically acceptable base.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-13 | 1980-12-13 | 1981-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-13 | 1984-12-13 | 1985-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-13 | 1988-12-13 | 1989-06-14 | $7700.00 | Window Closed / Lapsed |